EROAD was not a naive company entering the US. It had government contracts, a technically superior product, and a dedicated North American leadership structure. It also had a capital plan calibrated to a competitive intensity that the US fleet telematics market did not share. A forensic teardown of the undercapitalisation and competitive miscalculation that made the retreat inevitable.
“Not getting more traction in North America” — Mark Heine, outgoing EROAD CEO, on his first regret.
— BusinessDesk, Mark Heine on EROAD regrets and the road ahead
Founded in Auckland in 2000, EROAD built electronic road user charging and fleet telematics technology for heavy vehicles. The product solved a specific and genuine regulatory problem: New Zealand’s road user charging system requires diesel vehicles to pay per kilometre travelled, and EROAD’s device made that tracking accurate, tamper-evident, and automated. By the time the company listed on the NZX in 2014, it had won the NZ Transport Agency as a customer, held approximately 40% of its home market, and had expanded into Australia and Oregon — where the state had implemented a voluntary per-mile road usage charge programme analogous to NZ’s system.
The US entry thesis had genuine structural logic. Several US states were actively exploring vehicle miles travelled (VMT) charges as a replacement for the fuel excise tax — a policy direction accelerated by the rise of electric vehicles that pay no fuel tax at all. EROAD had built the exact technology these programmes needed. Oregon’s OReGO programme was already running on EROAD hardware. The company had first-mover credibility in the nascent US road usage charging category, relationships with state transport agencies, and a product that had been proven in a real regulatory environment.
The NZ$135 million goodwill impairment in EROAD’s financial results and the strategic pivot back to ANZ did not happen because the product was wrong or the market was nonexistent. They happened because the competitive intensity in the broader US fleet telematics market — the market EROAD had to compete in while waiting for VMT programmes to scale — was categorically different from anything EROAD had experienced at home.
EROAD’s North American strategy operated on two tracks simultaneously. The first was the regulatory track: positioning as the technology partner for US states implementing VMT charging programmes, leveraging the Oregon relationship as the reference deployment, and building the government relationships needed to win state-level contracts as the policy environment shifted. The second was the commercial track: competing in the broader fleet telematics market — GPS tracking, electronic logging devices (ELDs), driver behaviour monitoring, compliance management — to build revenue while the regulatory opportunity matured.
The dual-track strategy was structurally sound in design. The problem was that the commercial track required EROAD to compete in a US fleet telematics market dominated by companies that were larger, better-capitalised, and more deeply embedded in the US trucking industry than any NZ company had the resources to challenge at scale. And the regulatory track moved on a policy timeline that EROAD could not control and could not accelerate.
2014: NZX listing. US entry underway through Oregon OReGO programme. 2018–2019: Significant North American investment. Co-CEO model established with dedicated North American leadership. US operations scaled up. Revenue growing but not at the rate the capital deployment implied. 2022: NZ$146 million first-half net loss driven by NZ$135 million goodwill impairment reflecting “termination of a legacy customer, competitive dynamics and economic conditions in the North American market.” North American co-CEO steps down. Revenue guidance downgraded. Explicit company statement that North America “had not been delivering to expectations.” Strategic pivot announced: EROAD would prioritise NZ and Australia, treating North America as a managed rather than growth operation. Outgoing CEO Mark Heine, on his departure, names “not getting more traction in North America” as his first regret. Trump administration tariffs later cause EROAD to lose a major US customer — a final blow to an already retreating North American position.
EROAD’s North American failure was not a product failure or a leadership failure. The product was technically credible. The leadership was experienced. The failure was a capital allocation problem built on a competitive intensity miscalculation — and a policy timeline dependency that the company could not control.
In New Zealand, EROAD competed in a market where the regulatory requirement — electronic road user charging for diesel vehicles — was mandatory and EROAD held a dominant position as the government-approved provider. The competitive dynamics were shaped by regulation, not by sales intensity. Winning in NZ required building a product that met the Transport Agency’s specifications and demonstrating reliability at scale. It did not require competing against a dozen well-capitalised US technology companies for the discretionary telematics budget of American fleet managers.
The US fleet telematics market in the 2010s and early 2020s was one of the most competitively saturated enterprise technology categories in North America. Samsara listed on Nasdaq in 2021 at a valuation of over US$11 billion. Verizon Connect (backed by Verizon’s infrastructure), Omnitracs (backed by Vista Equity Partners), and Trimble had collectively spent decades building relationships with the US trucking industry, embedding their software into fleet management workflows, and competing for every major fleet contract with marketing and sales resources that no NZ company could match at equivalent stage.
EROAD entered this market with a genuinely good product and a capital base sized for the NZ competitive environment. The gap between those two realities — NZ-scale capital against US-scale competition — is the structural reason the North American strategy never reached the traction required to justify the investment. This is not a failure that better execution could have fixed. It required a fundamentally different capital plan from the outset.
The most defensible part of EROAD’s US thesis — VMT charging as the technology infrastructure for a policy shift that was already underway — was also the most timeline-dependent. Government policy adoption in the US moves at a pace determined by legislative cycles, funding availability, political will, and interstate coordination that no vendor can influence materially. Oregon’s OReGO programme, launched in 2015, remained a voluntary pilot more than a decade later. Federal VMT pilot programmes authorised under the Infrastructure Investment and Jobs Act of 2021 were still in research and development phases through 2024.
EROAD needed the commercial track — competing in the broader fleet telematics market — to generate sufficient revenue to fund the company through the years it would take for the regulatory opportunity to reach commercial scale. That commercial track required competing against Samsara, Verizon Connect, and Trimble with a fraction of their capital. The commercial track could not generate enough revenue to sustain the operation, and the regulatory track could not be accelerated. The company was caught between a timeline it could not control and a competitive environment it could not afford to win.
The NZ$135 million goodwill impairment was triggered in part by the “termination of a legacy customer” — a single US customer whose departure materially impacted the North American revenue position. A business whose financial model depends on retaining a small number of large US accounts has not built a channel or a customer base. It has built a dependency. When the customer leaves — for a competitor, for an in-house solution, for a contract renegotiation that EROAD could not match — the impairment follows.
This is a specific manifestation of the broader channel under-design problem. EROAD’s North American revenue was concentrated in a small number of accounts rather than distributed across a large, diversified customer base that could absorb individual losses. Building that diversified base requires either a direct sales organisation at scale — expensive — or channel partners who bring their own customer relationships to the table. EROAD had neither in sufficient depth to insulate the North American business against single-account churn.
The Trump administration tariff environment that later caused EROAD to lose an additional major US customer was not structurally predictable, but it illustrates the same underlying fragility: a North American business whose performance depends on retaining specific accounts in a specific policy environment is exposed to forces that NZ-headquartered companies cannot anticipate or manage from 12,000 kilometres away.
THE IMPAIRMENT
Goodwill impairment booked in EROAD’s first-half results, reflecting the North American retreat — driven by customer termination, competitive dynamics, and economic conditions
The NZ$135 million impairment represented the gap between what EROAD had paid to build its North American position and what that position was actually worth once the customer losses and competitive reality were priced in. Capital deployed into a market where the competitive intensity was systematically underestimated cannot be recovered by working harder.
FAILURE DIMENSION ANALYSIS — EROAD
The NZ$146 million first-half net loss — driven by the NZ$135 million goodwill impairment — was the moment EROAD’s North American strategy moved from “underperforming” to “structurally unviable at current capitalisation.” Goodwill impairments are accounting events, but they are also strategic admissions: the value that was recorded when the North American position was built is no longer there. The business that was expected to generate the returns justifying that value has not materialised.
The departure of the North American co-CEO at the same time as the impairment was the operational confirmation of the accounting signal. When both the financial model and the leadership structure built around a strategic bet are dismantled simultaneously, the company has concluded that the bet cannot be won at the capital level available. The pivot to prioritising NZ and Australia was not a tactical adjustment — it was the strategic acknowledgement that North America required a different scale of commitment than EROAD could provide.
The subsequent loss of a major US customer due to Trump administration tariff impacts — after the strategic pivot had already been announced — confirmed what the impairment had already priced in: the North American business was too exposed to individual account relationships and external policy forces to sustain without a capital commitment that was not available.
EROAD’s North American failure is one of the most structurally honest in NZ corporate history — partly because the outgoing CEO named it explicitly as a regret rather than attributing it to external forces. The product was technically superior. The regulatory thesis was correct in direction if not in timeline. The team was experienced. The failure was a capital allocation decision: deploying NZ-scale capital into a market that required US-scale capital to compete, and accepting a policy timeline dependency that could not be accelerated regardless of execution quality.
This is the EROAD lesson for NZ companies entering the US in regulated or semi-regulated categories: the regulatory thesis may be right, but the commercial bridge you need to fund yourself while the regulation matures requires competing in the adjacent commercial market — and that market is judged on US capital and competitive intensity terms, not on the regulatory insight that drove the entry decision.
Before entering a US market on a regulatory thesis, model what the commercial bridge looks like. If your primary US opportunity depends on a government policy adoption timeline you cannot control, you need a commercial revenue stream to sustain the operation while you wait. That commercial revenue stream will be generated in the existing competitive market — and that market is judged on its own terms, not on the regulatory insight that drove your entry. Map the capital required to compete commercially at US-scale intensity before committing to the regulatory strategy.
Single-account concentration is not a US distribution strategy. If the financial viability of your North American operation depends on retaining two or three large accounts, you have not built a business in the US — you have built an account management relationship that is exposed to churn, competitive displacement, and policy changes you cannot anticipate from Auckland. Before scaling North American headcount and overhead, ensure the account base is diversified enough to absorb the loss of any single customer without triggering a strategic review.
Size the capital commitment to the competitive environment you are entering, not to the one you are leaving. EROAD competed in NZ against a manageable set of incumbents in a regulation-shaped market. The US fleet telematics market was competed for by companies capitalised at 10–50x EROAD’s scale. The decision to enter that market at NZ-scale capitalisation was a structural mismatch between ambition and resource that no quality of execution could fully overcome.
EROAD’s North American story is the NZ corporate case study in what happens when a company enters the US on the strength of a genuinely correct regulatory thesis — and then discovers that the commercial market it needs to survive while the regulation matures is a different and far more competitive battle than the one the thesis implied.
A pre-entry US architecture for EROAD would have forced two questions before the North American capital commitment was made. First: what is the capital required to compete commercially in US fleet telematics — not against the NZ incumbent set, but against Samsara, Verizon Connect, and Trimble — and is that capital available? Second: what is the realistic VMT policy adoption timeline in the three to five states most likely to implement commercial programmes, and what is the revenue bridge required to fund the operation through that timeline? If the answers to those questions produced a capital requirement that EROAD could not fund, the right decision was a narrower entry: fewer states, fewer commercial verticals, lower overhead, deeper positioning in the specific regulatory niche where EROAD had a genuine right to win.
The CEO’s regret is the most honest summary available. It was not a bad product. It was not a bad team. It was a capital plan that was not sized for the market it was entering.
“The regulatory thesis may be right. But the commercial bridge you need while the regulation matures requires competing in a market that is judged on US capital and competitive intensity terms — not on the policy insight that drove the entry.”
— PIVOTAL CATALYST VERDICT
FREQUENTLY ASKED
Was EROAD’s US failure caused by the Trump tariffs?
The tariffs were a final blow to an already retreating position, not the cause of the retreat. The strategic pivot away from North America and the NZ$135 million goodwill impairment both preceded the tariff-related customer loss. The impairment reflected the cumulative gap between the North American capital deployment and the revenue and market position it had generated — driven by competitive intensity and customer concentration risk that existed independently of the tariff environment.
Was the VMT regulatory thesis wrong?
The directional thesis was correct — US states are moving toward vehicle miles travelled charging, and EROAD’s technology is genuinely suited to that environment. The problem was the commercial bridge required to fund the company through the years between thesis and policy implementation. That bridge required competing in the broader fleet telematics market at a capital intensity that EROAD could not sustain. The thesis was right. The capital plan for waiting while the thesis proved out was wrong.
What should NZ companies with a US regulatory thesis do differently?
Treat the regulatory thesis and the commercial bridge as two separate business design problems. The regulatory opportunity shapes which market to enter and which government relationships to build. The commercial bridge is a separate question: what is the minimum viable commercial operation that generates enough revenue to fund the company while the regulation matures, and can it be built and sustained at the capital available? If the commercial bridge requires competing at US-scale intensity with NZ-scale capital, the entry either needs more capital or a narrower scope — not a broader one.
Go In Knowing
The US Entry Diagnostic delivers a structurally sound plan to enter the US before you invest $500,000 in painful mistakes.
Book the Paid Diagnostic$10,000 NZD. Credited in full toward any engagement.